Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
James Isaacs(Duke Medical Center), Jeremy Force(Daiichi Sankyo (Germany)), Heather L. McArthur(Southwestern Medical Center), Carey K. Anders(Duke University)
Cited by 72
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795